drugset / Trial / NCT00390676
A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
Non-randomizedSingle-groupOpen-labelTreatment
Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.
Timeline
- Start
- 2006-11
- Primary completion
- —
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADH-1 | Protein / enzyme biologic | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |